Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | CETP | P11597 | 3/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | ALPG | P10696 | 1/20 | 0.40 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30697402 | 0.95 | TSHR (0.55) | TSHRCETPLTA4HEPHX2SRC | |
| SCHEMBL30697407 | 0.89 | TSHR (0.46) | TSHRCETPLTA4HEPHX2SRC | |
| SCHEMBL5028595 | 0.89 | TSHR (0.60) | TSHRCETPSRCPDPK1MTOR | |
| SCHEMBL4839007 | 0.83 | TSHR (0.53) | TSHRCETP | |
| SCHEMBL11148077 | 0.82 | TSHR (0.52) | TSHRCETPSRCPDPK1MTOR | |
| SCHEMBL3360553 | 0.82 | TSHR (0.52) | TSHRCETP | |
| SCHEMBL31308108 | 0.81 | CETP (0.55) | TSHRCETP | |
| SCHEMBL4641409 | 0.81 | TSHR (0.64) | TSHRCETPSRCPDPK1MTOR | |
| SCHEMBL7265466 | 0.81 | CETP (0.71) | TSHRCETP | |
| SCHEMBL13537727 | 0.81 | CETP (0.50) | TSHRCETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4543893-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AND CONJUGATES FOR THE TREATMENT OF CANCER | Evexta Bio (FR) | 2025-04-30 | — | — | EP | disclosed |
| WO-2024003002-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AND CONJUGATES FOR THE TREATMENT OF CANCER | DIACCURATE (FR) | 2024-01-04 | — | — | WO | disclosed |
| US-20110218177-A1 | PRODRUGS OF OXAZOLIDINONE CETP INHIBITORS | MERCK SHARP & DOHME LLC | 2011-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218177-A1 | PRODRUGS OF OXAZOLIDINONE CETP INHIBITORS | CETP, SLCO2B1, OXA1L | TSHR 3227/4885CETP 1/4885LTA4H 1218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.